General information

Announcements(0)

Program

Sessions

Search presentations

Timetable

Wed. Dec 3, 2025

Thu. Dec 4, 2025

Fri. Dec 5, 2025

web_header_en.png

web_icon.png

Profile management

Announcements

Bookmark

Download PDF for print

Program Type

Login required to view

Password required to view

Presentation Information

Session Details

Please enter the password printed on your name card.

To browse or post comments, you must log in.

You cannot post comments as it is outside the comment posting period.

This comment has been deleted. You cannot reply to this comment.

MIKE-1 Phase 1-2 Trial of Tamibarotene (AM80) plus gemcitabine and nab-paclitaxel: Stromal Reprogramming Therapy for Pancreatic Cancer via Induction of Meflin-positive tumor-restraining CAFs

Traditionally viewed as structural support cells, fibroblasts have emerged as key players in diverse physiological and pathological processes, including stem cell niche maintenance, tissue repair, tumor microenvironment formation, and organ fibrosis progression. Elucidating the molecular mechanisms that regulate this multifunctional nature of fibroblasts represents a critical challenge for understanding homeostatic regulation and developing novel therapeutic strategies. This symposium brings together leading researchers to share cutting-edge findings on fibroblasts present in various tissues and those originating from different cellular lineages, aiming to deepen our fundamental understanding of these enigmatic cells and their complex regulatory networks.

【E】Deciphering Fibroblast Molecular Biology: A Lineage and Multipotency Perspective

The 48th Annual Meeting of the Molecular Biology Society of Japan

Presentation Information

[1PS-11-06]MIKE-1 Phase 1-2 Trial of Tamibarotene (AM80) plus gemcitabine and nab-paclitaxel: Stromal Reprogramming Therapy for Pancreatic Cancer via Induction of Meflin-positive tumor-restraining CAFs

Comment